Yunnan Baiyao Group Co.,ltd
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Yunnan Baiyao Group Co., Ltd. was founded in 1902, integrating brand, product, and company name. It is widely recognized in the industry as the most innovative representative of China's time-honored brand. With a brand value of over 30 billion yuan, it ranks among the top 4 pharmaceutical companies in China and 120th among traditional Chinese medicine companies. In July 2021, it was selected as one of the top 25 global pharmaceutical brand values and the strongest pharmaceutical brand in China. It was also ranked 34th among global pharmaceutical companies in 2021. In 1970, Premier Zhou Enlai approved the establishment of Yunnan Baiyao Special Factory. In 1993, it was listed as the first stock in Yunnan, and in 1999, it underwent a comprehensive modernization of enterprise restructuring. From 2016 to 2019, it completed mixed reform and overall listing, laying a solid institutional and institutional foundation for the company to create another century of glory. The white medicine mixed reform is known as the "white medicine model" for its pioneering nature, and has received attention, research, and reference from all sectors of society. Through mixed reform and overall listing, state-owned and private assets have become the two major shareholders of Baiyao (each accounting for 25.14% of the equity), forming a shareholding structure without actual controllers. The governance structure and operating mechanism are highly market-oriented, and all directors, supervisors, and senior executives are de administrative, no longer retaining all the benefits of state-owned enterprise leaders. They become fully market-oriented professional managers, and undergo market-oriented selection, compensation, and evaluation and assessment. The shareholders' meeting takes the reform of the salary management system as the starting point to promote the establishment of incentive mechanisms. Currently, two rounds of employee stock ownership incentives have been completed. The company adopts a light asset model with strong innovation and profitability. The company is committed to bringing traditional Chinese medicine into modern life, developing from a bottle of powder to one of the leaders in China's major health industry, covering four major sectors: drugs, personal care health products, traditional Chinese medicine resources, and pharmaceutical logistics. There are 36 categories and 390 varieties of products, with 11 products selling over 100 million yuan per product. Toothpaste, aerosols, band-aids, ointments, and other related products rank first in the country. The company adopts a business unit system to develop its existing business, which is divided into drug, health products, traditional Chinese medicine resource business units and Yunnan Pharmaceutical Co., Ltd. (responsible for pharmaceutical logistics business). Each business unit has its own responsibilities and collaborates with each other, and its main business has reached a leading level in the country. Deploying factories in Kunming, Dali, Wenshan, Lijiang, Wuding, as well as Wuxi, Jiangsu, Hefei, Anhui, etc., with sales channels covering the whole country. The company regards safeguarding life and health as its corporate mission and is committed to becoming a leading provider of comprehensive medical and health solutions. Based on the above mission and vision, Yunnan Baiyao has established the strategic goal of "1+4+1" (traditional Chinese medicine+oral, skin, bone injury, female care+digitalization) on the basis of consolidating its existing business, optimized the industry and research and development system, and completed its layout in Beijing, Shanghai, Hong Kong, Hainan, and South Korea. It has become an important strategic support for Baiyao to gather global resources and serve the Chinese market. Basic research, commercial development, and Business in product innovation and marketing. The company adopts the "six major innovation" approach of technological innovation, business model innovation, product innovation, organizational innovation, talent innovation, and brand revitalization, adopting the "four wheel drive" model of marketing, innovation, capital, and digitalization, striving to achieve significant growth and breakthroughs as soon as possible, and contributing to the development and leap of China's pharmaceutical and health industry. |
| Headquarter | Kunming |
| Establish Date | 11/30/1993 |
| Listed Code | 000538.SZ |
| Listed Date | 12/15/1993 |
| Chairman | Dong Ming. |
| CEO | Dong Ming. |
| Website | www.yunnanbaiyao.com.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
